Puma Biotechnology, Inc., a biopharmaceutical company, announced the initiation of its ALISertib in CAncer Phase II trial of alisertib monotherapy for the treatment of...
Invitae, a leading medical genetics company, announced new research published in Nature describing the first use of the company's personalized cancer monitoring (PCM) platform to...
